MBL Wealth LLC Acquires 18,987 Shares of Boston Scientific Corporation $BSX

MBL Wealth LLC boosted its holdings in Boston Scientific Corporation (NYSE:BSX) by 306.0% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 25,191 shares of the medical equipment provider’s stock after buying an additional 18,987 shares during the period. MBL Wealth LLC’s holdings in Boston Scientific were worth $1,100,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. GraniteShares Advisors LLC increased its position in shares of Boston Scientific by 1.5% in the first quarter. GraniteShares Advisors LLC now owns 13,599 shares of the medical equipment provider’s stock worth $853,000 after acquiring an additional 195 shares in the last quarter. Avantax Planning Partners Inc. lifted its holdings in shares of Boston Scientific by 4.0% during the 1st quarter. Avantax Planning Partners Inc. now owns 5,242 shares of the medical equipment provider’s stock valued at $329,000 after acquiring an additional 201 shares in the last quarter. WPG Advisers LLC lifted its holdings in shares of Boston Scientific by 11.9% during the 1st quarter. WPG Advisers LLC now owns 1,916 shares of the medical equipment provider’s stock valued at $120,000 after acquiring an additional 203 shares in the last quarter. Natural Investments LLC boosted its position in Boston Scientific by 1.3% during the 2nd quarter. Natural Investments LLC now owns 16,067 shares of the medical equipment provider’s stock worth $685,000 after purchasing an additional 206 shares during the period. Finally, 180 Wealth Advisors LLC boosted its position in Boston Scientific by 3.6% during the 1st quarter. 180 Wealth Advisors LLC now owns 6,468 shares of the medical equipment provider’s stock worth $406,000 after purchasing an additional 223 shares during the period. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Price Performance

BSX opened at $45.67 on Friday. The company has a fifty day simple moving average of $45.46 and a 200 day simple moving average of $49.16. The firm has a market cap of $66.19 billion, a price-to-earnings ratio of 18.49, a PEG ratio of 1.11 and a beta of 0.58. Boston Scientific Corporation has a twelve month low of $41.38 and a twelve month high of $105.65. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. During the same quarter in the previous year, the firm posted $0.75 EPS. The firm’s quarterly revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Equities research analysts expect that Boston Scientific Corporation will post 3.24 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently issued reports on BSX. Needham & Company LLC lowered their price target on Boston Scientific from $77.00 to $57.00 and set a “buy” rating for the company in a report on Wednesday, July 8th. Evercore reduced their price objective on Boston Scientific from $65.00 to $52.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 7th. Mizuho set a $55.00 target price on Boston Scientific in a research report on Tuesday, October 13th. Canaccord Genuity Group lowered their target price on Boston Scientific from $70.00 to $66.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Finally, Oppenheimer dropped their target price on Boston Scientific from $85.00 to $65.00 and set an “outperform” rating on the stock in a report on Monday, September 21st. One analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Boston Scientific has an average rating of “Moderate Buy” and a consensus price target of $68.23.

Insider Transactions at Boston Scientific

In other Boston Scientific news, Director David Habiger purchased 2,100 shares of the business’s stock in a transaction that occurred on Wednesday, August 5th. The shares were acquired at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the purchase, the director owned 17,160 shares in the company, valued at $816,644.40. The trade was a 13.94% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Michael Mahoney purchased 186,240 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The stock was acquired at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the purchase, the chief executive officer owned 1,590,024 shares of the company’s stock, valued at approximately $76,845,859.92. This represents a 13.27% increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders have acquired 194,522 shares of company stock valued at $9,385,210. 0.34% of the stock is currently owned by insiders.

Boston Scientific Profile

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.